WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006088438) BIOMARKERS FOR INTERFERON-ALPHA RESPONSE IN HEPATITIS C VIRUS INFECTED PATIENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/088438    International Application No.:    PCT/US2004/040545
Publication Date: 24.08.2006 International Filing Date: 14.02.2005
IPC:
C12Q 1/68 (2006.01)
Applicants: APPLERA CORPORATION [US/US]; APPLERA CORPORATION, 1401 Harbor Bay Parkway, Alameda, California 94502-7070 (US) (For All Designated States Except US).
CHANG, Sheng-Yung P. [US/US]; (US) (For US Only).
MARTIN, John W. [US/US]; (US) (For US Only)
Inventors: CHANG, Sheng-Yung P.; (US).
MARTIN, John W.; (US)
Agent: SEPERACK, Peter K.; APPLERA CORPORATION, 1401 Harbor Bay Parkway, Alameda, CA 94592-7070 (US)
Priority Data:
Title (EN) BIOMARKERS FOR INTERFERON-ALPHA RESPONSE IN HEPATITIS C VIRUS INFECTED PATIENTS
(FR) BIOMARQUEURS DE LA RÉPONSE INTERFÉRON-ALPHA CHEZ LES PATIENTS INFECTÉS PAR LE VIRUS DE L'HÉPATITE C
Abstract: front page image
(EN)The present invention relates to the identification of prognostic markers useful in determining the response of hepatitis c virus (HCV) infected patients to interferon alpha (IFN-a) treatment. The studies provide biomarkers that can be used to discern sustained responders and non-responders of IFN-a treatment. This information should enable treating physicians to help patients to make more informed decisions.
(FR)La présente invention concerne l'identification de marqueurs de diagnostic pouvant être employés dans la mesure de la réponse de patients infectés par le virus de l'hépatite C (VHC) à un traitement par interférons alpha (IFN-a). Les études ont mené à l'identification de biomarqueurs pouvant être employés afin de distinguer les répondeurs prolongés des non-répondeurs d'un traitement par IFN-a. Ces informations doivent permettre aux médecins d'aider les patients à prendre des décisions plus éclairées.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)